BioStem Technologies (BSEM) Stock Overview
Engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BSEM Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
BioStem Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.68 |
| 52 Week High | US$15.50 |
| 52 Week Low | US$3.09 |
| Beta | 0.18 |
| 1 Month Change | -9.67% |
| 3 Month Change | 1.96% |
| 1 Year Change | -63.24% |
| 3 Year Change | 134.00% |
| 5 Year Change | 222.76% |
| Change since IPO | -99.47% |
Recent News & Updates
Shareholder Returns
| BSEM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.8% | -2.6% | 3.4% |
| 1Y | -63.2% | 37.2% | 34.6% |
Return vs Industry: BSEM underperformed the US Pharmaceuticals industry which returned 37.2% over the past year.
Return vs Market: BSEM underperformed the US Market which returned 34.6% over the past year.
Price Volatility
| BSEM volatility | |
|---|---|
| BSEM Average Weekly Movement | 21.3% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: BSEM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BSEM's weekly volatility has increased from 16% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Jason Matuszewski | biostemtechnologies.com |
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014.
BioStem Technologies, Inc. Fundamentals Summary
| BSEM fundamental statistics | |
|---|---|
| Market cap | US$82.47m |
| Earnings (TTM) | -US$6.58m |
| Revenue (TTM) | US$47.48m |
Is BSEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSEM income statement (TTM) | |
|---|---|
| Revenue | US$47.48m |
| Cost of Revenue | US$3.04m |
| Gross Profit | US$44.44m |
| Other Expenses | US$51.02m |
| Earnings | -US$6.58m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 93.59% |
| Net Profit Margin | -13.86% |
| Debt/Equity Ratio | 7.7% |
How did BSEM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/15 00:08 |
| End of Day Share Price | 2026/04/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioStem Technologies, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bradley Sorensen | Zacks Small-Cap Research |